Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04909801




Registration number
NCT04909801
Ethics application status
Date submitted
28/05/2021
Date registered
2/06/2021
Date last updated
15/10/2024

Titles & IDs
Public title
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Scientific title
A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment With Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate
Secondary ID [1] 0 0
2020-000350-96
Secondary ID [2] 0 0
IM101-863
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Abatacept
Treatment: Drugs - Adalimumab
Treatment: Drugs - Methotrexate

Experimental: Arm 1: Abatacept + Methotrexate -

Experimental: Arm 2: (Adalimumab + Methotrexate) followed by (Abatacept + Methotrexate) -


Treatment: Drugs: Abatacept
Abatacept SC (125 mg) once weekly

Treatment: Drugs: Adalimumab
Adalimumab SC (40 mg) once every 2 weeks

Treatment: Drugs: Methotrexate
Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
Timepoint [1] 0 0
Baseline, week 24
Secondary outcome [1] 0 0
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24
Timepoint [1] 0 0
Week 24
Secondary outcome [2] 0 0
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
Timepoint [2] 0 0
Baseline, week 24
Secondary outcome [3] 0 0
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24
Timepoint [3] 0 0
Week 24
Secondary outcome [4] 0 0
Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24
Timepoint [4] 0 0
Baseline, week 24
Secondary outcome [5] 0 0
Percentage of SE+ Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
Timepoint [5] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [6] 0 0
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
Timepoint [6] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [7] 0 0
Percentage of SE+ Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
Timepoint [7] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [8] 0 0
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
Timepoint [8] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [9] 0 0
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
Timepoint [9] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [10] 0 0
Percentage of SE+ Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
Timepoint [10] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [11] 0 0
Percentage of Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
Timepoint [11] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [12] 0 0
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
Timepoint [12] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [13] 0 0
Percentage of Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
Timepoint [13] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [14] 0 0
Percentage of Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
Timepoint [14] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [15] 0 0
Percentage of Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
Timepoint [15] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [16] 0 0
Percentage of Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
Timepoint [16] 0 0
Day 29, 57, 85, 113, 141, 169
Secondary outcome [17] 0 0
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for SE+ Participants
Timepoint [17] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [18] 0 0
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for SE+ Participants
Timepoint [18] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [19] 0 0
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for SE+ Participants
Timepoint [19] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [20] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for SE+ Participants
Timepoint [20] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [21] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for SE+ Participants
Timepoint [21] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [22] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for SE+ Participants
Timepoint [22] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [23] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for SE+ Participants
Timepoint [23] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [24] 0 0
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for All Participants
Timepoint [24] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [25] 0 0
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for All Participants
Timepoint [25] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [26] 0 0
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for All Participants
Timepoint [26] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [27] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for All Participants
Timepoint [27] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [28] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for All Participants
Timepoint [28] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [29] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for All Participants
Timepoint [29] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [30] 0 0
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for All Participants
Timepoint [30] 0 0
Baseline, day 29, 57, 85, 113, 141, 169
Secondary outcome [31] 0 0
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) Over Time for SE+ Participants
Timepoint [31] 0 0
Up to week 24
Secondary outcome [32] 0 0
Adjusted Mean Change From Baseline in SF-36 Over Time for All Participants
Timepoint [32] 0 0
Up to week 24
Secondary outcome [33] 0 0
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for SE+ Participants
Timepoint [33] 0 0
Up to week 24
Secondary outcome [34] 0 0
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for All Participants
Timepoint [34] 0 0
Up to week 24

Eligibility
Key inclusion criteria
* Early rheumatoid arthritis (RA), defined as symptoms of RA that started = 12 months prior to screening and satisfied the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria for the classification of RA at some point during the 12-month period
* Naïve to any targeted (biologic or nonbiologic) disease-modifying antirheumatic drugs (DMARDs), conventional synthetic DMARDs other than methotrexate (MTX), or investigational therapies for RA
* Treated with MTX for at least 12 weeks, with a stable dose of oral or parenteral MTX for at least 4 weeks prior to randomization
* Anti-cyclic citrullinated peptide-2 (Anti-CCP-2) test that is > 3× the upper limit of normal and are positive for rheumatoid factor (RF) according to central lab testing during screening
* At least a Disease Activity Score 28-joint count calculated using C-reactive protein (DAS28-CRP) = 3.2 at screening
* At least 3 tender and at least 3 swollen joints at screening and at randomization
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Women who are breastfeeding
* Autoimmune disease other than RA (e.g., psoriasis, systemic lupus erythematosus [SLE], vasculitis, seronegative spondyloarthritis, inflammatory bowel disease, Sjogren's syndrome) or currently active fibromyalgia
* History of or current inflammatory joint disease other than RA (e.g., psoriatic arthritis, gout, reactive arthritis, Lyme disease)
* At risk for tuberculosis
* Recent acute infection
* History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis)
* History of infection of a joint prosthesis or artificial joint
* History of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis)
* History of primary immunodeficiency
* Current clinical findings or a history of a demyelinating disorder
* 5 or more joints cannot be assessed for tenderness or swelling

Other protocol-defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
3/09/2025
Actual
Sample size
Target
Accrual to date
Final
338
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Local Institution - 0072 - Botany
Recruitment hospital [2] 0 0
Local Institution - 0062 - Paramatta
Recruitment hospital [3] 0 0
Local Institution - 0063 - Maroochydore
Recruitment hospital [4] 0 0
Local Institution - 0102 - Woodville South
Recruitment hospital [5] 0 0
Local Institution - 0064 - Camberwell
Recruitment hospital [6] 0 0
Local Institution - 0065 - Geelong
Recruitment hospital [7] 0 0
Local Institution - 0105 - Ivanhoe
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
2150 - Paramatta
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
5001 - Woodville South
Recruitment postcode(s) [5] 0 0
3124 - Camberwell
Recruitment postcode(s) [6] 0 0
3220 - Geelong
Recruitment postcode(s) [7] 0 0
3079 - Ivanhoe
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Maryland
Country [4] 0 0
United States of America
State/province [4] 0 0
Minnesota
Country [5] 0 0
United States of America
State/province [5] 0 0
New Jersey
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Wisconsin
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Tucuman
Country [15] 0 0
Argentina
State/province [15] 0 0
Cordoba
Country [16] 0 0
Czechia
State/province [16] 0 0
Brno
Country [17] 0 0
Czechia
State/province [17] 0 0
Praha 2
Country [18] 0 0
France
State/province [18] 0 0
Montpellier
Country [19] 0 0
France
State/province [19] 0 0
Rouen
Country [20] 0 0
France
State/province [20] 0 0
Strasbourg
Country [21] 0 0
France
State/province [21] 0 0
Toulouse
Country [22] 0 0
Germany
State/province [22] 0 0
Berlin
Country [23] 0 0
Germany
State/province [23] 0 0
Bonn
Country [24] 0 0
Germany
State/province [24] 0 0
Freiburg
Country [25] 0 0
Germany
State/province [25] 0 0
Hamburg
Country [26] 0 0
Germany
State/province [26] 0 0
Planegg
Country [27] 0 0
Italy
State/province [27] 0 0
Catania
Country [28] 0 0
Italy
State/province [28] 0 0
Pavia
Country [29] 0 0
Italy
State/province [29] 0 0
Perugia
Country [30] 0 0
Italy
State/province [30] 0 0
Roma
Country [31] 0 0
Japan
State/province [31] 0 0
Aichi
Country [32] 0 0
Japan
State/province [32] 0 0
Fukuoka
Country [33] 0 0
Japan
State/province [33] 0 0
Hokkaido
Country [34] 0 0
Japan
State/province [34] 0 0
Miyagi
Country [35] 0 0
Japan
State/province [35] 0 0
Nagasaki
Country [36] 0 0
Japan
State/province [36] 0 0
Saitama
Country [37] 0 0
Japan
State/province [37] 0 0
Tokyo
Country [38] 0 0
Mexico
State/province [38] 0 0
Distrito Federal
Country [39] 0 0
Mexico
State/province [39] 0 0
Jalisco
Country [40] 0 0
Mexico
State/province [40] 0 0
SAN LUIS Potosi
Country [41] 0 0
Mexico
State/province [41] 0 0
Yucatán
Country [42] 0 0
Mexico
State/province [42] 0 0
Chihuahua
Country [43] 0 0
Poland
State/province [43] 0 0
Kujawsko-pomorskie
Country [44] 0 0
Poland
State/province [44] 0 0
Bydgoszcz
Country [45] 0 0
Poland
State/province [45] 0 0
Elblag
Country [46] 0 0
Spain
State/province [46] 0 0
A Coruña
Country [47] 0 0
Spain
State/province [47] 0 0
Madrid
Country [48] 0 0
Spain
State/province [48] 0 0
Santander
Country [49] 0 0
Switzerland
State/province [49] 0 0
Basel
Country [50] 0 0
Switzerland
State/province [50] 0 0
St. Gallen
Country [51] 0 0
Taiwan
State/province [51] 0 0
Kaohsiung Niao Sung Dist
Country [52] 0 0
Taiwan
State/province [52] 0 0
New Taipei City
Country [53] 0 0
Taiwan
State/province [53] 0 0
Taichung City
Country [54] 0 0
Taiwan
State/province [54] 0 0
Taichung
Country [55] 0 0
Taiwan
State/province [55] 0 0
Tainan
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Staffordshire
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Hull
Country [58] 0 0
United Kingdom
State/province [58] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT04909801